Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
FOLD Amicus Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: FOLD
Price (delayed)
$6.02
Market cap
$1.85B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$2.12B
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics
Highlights
The EPS has soared by 82% YoY and by 50% from the previous quarter
The net income has soared by 80% YoY and by 48% QoQ
Amicus Therapeutics's quick ratio has decreased by 6% from the previous quarter
Key stats
What are the main financial stats of FOLD
Market
Valuations
Earnings
Shares outstanding
307.93M
Market cap
$1.85B
Enterprise value
$2.12B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.33
Price to sales (P/S)
3.41
EV/EBIT
46.6
EV/EBITDA
39.45
EV/Sales
3.9
Revenue
$543.14M
Gross profit
$492.07M
Operating income
$40.93M
Net income
-$29.37M
EBIT
$45.4M
EBITDA
$53.63M
Free cash flow
$1.61M
Per share
Balance sheet
Liquidity
EPS
-$0.09
EPS diluted
-$0.09
Free cash flow per share
$0.01
Book value per share
$0.64
Revenue per share
$1.77
TBVPS
$1.87
Total assets
$789.84M
Total liabilities
$596.28M
Debt
$443.47M
Equity
$193.56M
Working capital
$357.91M
Debt to equity
2.29
Current ratio
3.34
Quick ratio
2.22
Net debt/EBITDA
4.88
Margins
Efficiency
Dividend
EBITDA margin
9.9%
Gross margin
90.6%
Net margin
-5.4%
Operating margin
7.5%
Return on assets
-3.8%
Return on equity
-16.8%
Return on invested capital
7.1%
Return on capital employed
7.1%
Return on sales
8.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FOLD stock price
How has the Amicus Therapeutics stock price performed over time
Intraday
-3.06%
1 week
-2.75%
1 month
-7.1%
1 year
-33.41%
YTD
-36.09%
QTD
-26.23%
Financial performance
How have Amicus Therapeutics's revenue and profit performed over time
Revenue
$543.14M
Gross profit
$492.07M
Operating income
$40.93M
Net income
-$29.37M
Gross margin
90.6%
Net margin
-5.4%
Amicus Therapeutics's operating income has surged by 154% YoY and by 65% QoQ
The operating margin has soared by 142% YoY and by 60% QoQ
FOLD's net margin has surged by 84% year-on-year and by 49% since the previous quarter
The net income has soared by 80% YoY and by 48% QoQ
Price vs fundamentals
How does FOLD's price correlate with its fundamentals
Growth
What is Amicus Therapeutics's growth rate over time
Valuation
What is Amicus Therapeutics stock price valuation
P/E
N/A
P/B
9.33
P/S
3.41
EV/EBIT
46.6
EV/EBITDA
39.45
EV/Sales
3.9
The EPS has soared by 82% YoY and by 50% from the previous quarter
The P/B is 50% below the 5-year quarterly average of 18.5 and 44% below the last 4 quarters average of 16.8
The equity has grown by 48% YoY
FOLD's price to sales (P/S) is 67% lower than its 5-year quarterly average of 10.2 and 41% lower than its last 4 quarters average of 5.8
FOLD's revenue is up by 28% year-on-year and by 2.8% since the previous quarter
Efficiency
How efficient is Amicus Therapeutics business performance
The ROIC has soared by 146% YoY and by 109% from the previous quarter
The ROS has soared by 140% YoY and by 115% from the previous quarter
Amicus Therapeutics's return on equity has surged by 85% YoY and by 52% QoQ
FOLD's ROA has soared by 81% YoY and by 49% from the previous quarter
Dividends
What is FOLD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FOLD.
Financial health
How did Amicus Therapeutics financials performed over time
FOLD's total assets is 32% greater than its total liabilities
FOLD's current ratio is up by 10% year-on-year
FOLD's total assets is up by 9% year-on-year
FOLD's debt is 129% greater than its equity
The equity has grown by 48% YoY
FOLD's debt to equity is down by 33% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.